Randall Hyer
CEO MERLIN Biotech, LLC.
Seminars
Tuesday 21st July 2026
CEO & mRNA Leaders Think Tank: From CAR-T Platforms, Gene Editing Triumphs & Cancer Immunotherapy Clinical Advances; Navigating mRNA’s Potential into New Therapies & Tools Towards Better Drugs for Patients Faster
9:00 am
- What are the future opportunities, promising targets and applications on the horizon for mRNA to achieve commercial success?
- How are recent mRNA and LNP platform acquisitions fueling next generation innovations from science to strategy?
- Linear, circular, self-amplifying, trans-amplifying RNA – Which modality offers the most efficiency?
- With clinical trials moving towards the far East and Australia, what opportunities does this open for the mRNA industry to progress faster to clinical validation?
Wednesday 22nd July 2026
Development of a Novel Immune Modulator Delivered via mRNA for Pediatric & Adult Solid Cancers: Pre-Clinical & Clinical Strategy
11:30 am
- USP6 (a de-ubiquitinase) has data in over 15 cancer types
- MER-101 (mRNA encoding USP6) is being studied in combination with checkpoint inhibitors in a humanized mouse model
- MER-101 is being developed for broad pediatric and adult indications including the rare pediatric Ewing sarcoma helping open a large adult market
